“The present scenario has exposed some structural weaknesses from the EU’s medicines supply chain plus a superior dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides explained. She advised that provide chain problems be tackled in an EU pharmaceutical approach anticipated to get released by the end